These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 12812486

  • 1. XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents.
    Hall MD, Foran GJ, Zhang M, Beale PJ, Hambley TW.
    J Am Chem Soc; 2003 Jun 25; 125(25):7524-5. PubMed ID: 12812486
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA.
    Anticancer Res; 2003 Jun 25; 23(3C):2757-65. PubMed ID: 12926110
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells.
    Hall MD, Dillon CT, Zhang M, Beale P, Cai Z, Lai B, Stampfl AP, Hambley TW.
    J Biol Inorg Chem; 2003 Sep 25; 8(7):726-32. PubMed ID: 12884089
    [Abstract] [Full Text] [Related]

  • 6. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
    Cubo L, Hambley TW, Sanz Miguel PJ, Carnero A, Navarro-Ranninger C, Quiroga AG.
    Dalton Trans; 2011 Jan 14; 40(2):344-7. PubMed ID: 20936210
    [Abstract] [Full Text] [Related]

  • 7. Investigations using fluorescent ligands to monitor platinum(IV) reduction and platinum(II) reactions in cancer cells.
    New EJ, Duan R, Zhang JZ, Hambley TW.
    Dalton Trans; 2009 Apr 28; (16):3092-101. PubMed ID: 19352538
    [Abstract] [Full Text] [Related]

  • 8. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
    Ali MS, Khan SR, Ojima H, Guzman IY, Whitmire KH, Siddik ZH, Khokhar AR.
    J Inorg Biochem; 2005 Mar 28; 99(3):795-804. PubMed ID: 15708801
    [Abstract] [Full Text] [Related]

  • 9. The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe.
    Ilinski P, Lai B, Cai Z, Yun W, Legnini D, Talarico T, Cholewa M, Webster LK, Deacon GB, Rainone S, Phillips DR, Stampfl AP.
    Cancer Res; 2003 Apr 15; 63(8):1776-9. PubMed ID: 12702562
    [Abstract] [Full Text] [Related]

  • 10. Application of fluorescence microscopy for investigation of cellular distribution of dinuclear platinum anticancer drugs.
    Kalayda GV, Zhang G, Abraham T, Tanke HJ, Reedijk J.
    J Med Chem; 2005 Aug 11; 48(16):5191-202. PubMed ID: 16078838
    [Abstract] [Full Text] [Related]

  • 11. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
    Xu Z, Wang Z, Yiu SM, Zhu G.
    Dalton Trans; 2015 Dec 14; 44(46):19918-26. PubMed ID: 26514681
    [Abstract] [Full Text] [Related]

  • 12. Hydrolysis triggers oxidation of a trans diamine platinum(II) anticancer complex.
    Pizarro AM, Munk VP, Navarro-Ranninger C, Sadler PJ.
    Angew Chem Int Ed Engl; 2003 Nov 10; 42(43):5339-42. PubMed ID: 14613170
    [No Abstract] [Full Text] [Related]

  • 13. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
    Choi S, Vastag L, Larrabee YC, Personick ML, Schaberg KB, Fowler BJ, Sandwick RK, Rawji G.
    Inorg Chem; 2008 Feb 18; 47(4):1352-60. PubMed ID: 18220340
    [Abstract] [Full Text] [Related]

  • 14. Platinum(II) complexes with l-methionylglycine and l-methionyl-l-leucine ligands: synthesis, characterization and in vitro antitumoral activity.
    Kaluderović GN, Schmidt H, Paschke R, Kalinowski B, Dietrich A, Mueller T, Steinborn D.
    J Inorg Biochem; 2007 Mar 18; 101(3):543-9. PubMed ID: 17223197
    [Abstract] [Full Text] [Related]

  • 15. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.
    Chaney SG, Gibbons GR, Wyrick SD, Podhasky P.
    Cancer Res; 1991 Feb 01; 51(3):969-73. PubMed ID: 1988140
    [Abstract] [Full Text] [Related]

  • 16. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
    Huo S, Shen S, Liu D, Shi T.
    J Phys Chem B; 2012 Jun 07; 116(22):6522-8. PubMed ID: 22574871
    [Abstract] [Full Text] [Related]

  • 17. Reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by aqueous extracts of cancer cells.
    Nemirovski A, Kasherman Y, Tzaraf Y, Gibson D.
    J Med Chem; 2007 Nov 15; 50(23):5554-6. PubMed ID: 17949066
    [Abstract] [Full Text] [Related]

  • 18. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V, Blanárová O, Svihálková-Sindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Fedorocko P, Kozubík A.
    Gynecol Oncol; 2006 Jul 15; 102(1):32-40. PubMed ID: 16364413
    [Abstract] [Full Text] [Related]

  • 19. XANES investigation of the Co oxidation state in solution and in cancer cells treated with Co(III) complexes.
    Bonnitcha PD, Hall MD, Underwood CK, Foran GJ, Zhang M, Beale PJ, Hambley TW.
    J Inorg Biochem; 2006 May 15; 100(5-6):963-71. PubMed ID: 16624414
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
    Coley HM, Sarju J, Wagner G.
    J Med Chem; 2008 Jan 10; 51(1):135-41. PubMed ID: 18072719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.